+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Viral Vectors Market - Global Forecast 2026-2032- Product Image
Viral Vectors Market - Global Forecast 2026-2032- Product Image
New

Viral Vectors Market - Global Forecast 2026-2032

  • PDF Icon

    Report

  • 185 Pages
  • January 2026
  • Region: Global
  • 360iResearch™
  • ID: 5666371
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The viral vectors market is undergoing structural transformation as technology integration, operational complexity, and evolving regulation converge, demanding new strategies from senior leaders.

Market Snapshot: Viral Vectors Market Growth & Trends

The Viral Vectors Market expanded from USD 2.15 billion in 2025 to USD 2.46 billion in 2026, and is forecast to advance at a CAGR of 14.63%, reaching USD 5.60 billion by 2032. This robust growth signals rising demand for advanced gene and cell therapy applications, supported by larger commercial manufacturing footprints, capacity expansion, and enhanced regulatory engagement.

Scope & Segmentation of the Viral Vectors Market

This report delivers a multi-dimensional segmentation framework tailored to inform decision making from preclinical design to commercial supply. It covers the full lifecycle of viral vector programs, integrating vector biology, therapeutic application, end user, and manufacturing stage contexts.

  • Vector Types: Adeno Associated Virus (AAV, including serotypes such as AAV2, AAV8, AAV9), Adenovirus, Lentivirus, and Retrovirus, each influencing clinical and manufacturing strategies.
  • Applications: Cell Therapy (spanning CAR-T, Dendritic, and TCR-T modalities), Gene Therapy (divided into Ex Vivo and In Vivo approaches), Vaccines (Prophylactic, Therapeutic), and Research (Basic, Preclinical).
  • Therapeutic Focus: Cardiovascular Disorders, Infectious Disease, Neurological Disorders (neurodegenerative and neurodevelopmental), Oncology (solid tumor, hematology), and Rare Diseases, each with distinct workflow and scalability demands.
  • End Users: Biopharma Companies, Hospitals and Clinics, and Research Institutes, each with unique regulatory and procurement requirements impacting commercialization and partnership models.
  • Manufacturing Stages: Upstream (Cell Expansion, Harvesting, Transfection) and Downstream (Filtration, Formulation, Purification—Chromatography, Ultracentrifugation) activities, plus differentiation between Clinical (Phases I–III) and Commercial scale operations.
  • Regional Focus: Americas (noted for innovation density and clinical integration), Europe, Middle East & Africa (harmonized regulatory structures, growing CDMO footprint), Asia-Pacific (accelerating trial activity, infrastructure support, cost advantage).

Key Takeaways: Strategic Insights for Viral Vector Decision-Makers

  • Holistic lifecycle management is now essential, linking early-stage vector engineering with downstream commercialization and long-term supply decisions.
  • Technological integration of design and manufacturing enables scalable, consistent production, driven by advances in capsid engineering, promoter selection, and process intensification.
  • Supply chain resilience, including dual sourcing and regional diversification, is increasingly prioritized to address material dependencies, regulatory changes, and global input volatility.
  • Outsourcing and partnership models are evolving, as CDMOs now offer end-to-end capabilities, absorb regulatory risks, and anchor competitive supply collaborations.
  • Local manufacturing, flexible procurement, and scenario-based planning have grown in strategic value amid tariff-driven cost pressures and shifting global trade environments.
  • Operational excellence, robust analytics, and talent development are becoming core differentiators for market leaders, as organizations face rising quality and compliance expectations.

Tariff Impact on Procurement and Supply Strategies

The introduction of tariffs in 2025 led to immediate increases in input costs for consumables and equipment, amplifying the need for supplier qualification, dual sourcing, and rigorous total cost analysis. Organizations revised procurement strategies, implemented contingency inventories, and renegotiated CDMO agreements to better allocate tariff-related risk. Capital investments shifted toward onshoring and modular facility adaptation to manage cost volatility, as upstream research operations adapted workflows to reflect pricing fluctuations and maintain project timelines.

Methodology & Data Sources

This analysis relies on a mixed-methods approach, integrating structured interviews with experts in biopharma, CDMOs, regulatory, and manufacturing roles with technical literature and secondary data validation. Triangulation methodology and sensitivity checks underpin the reliability of key findings, while feasibility assessments draw on operational data and supplier inputs for practical relevance.

Why This Report Matters

  • Provides a data-driven, actionable playbook for aligning technology, procurement, and supply chain strategies throughout the viral vector lifecycle.
  • Equips executives to anticipate regulatory shifts, navigate global input volatility, and optimize capital investment decisions across development and manufacturing functions.
  • Enables the design of collaborative partnerships, supporting risk management and accelerating clinical progression in a dynamic policy environment.

Conclusion

Structural change in the viral vectors market now rewards organizations that integrate scientific advances with resilient supply, flexible operations, and collaborative models. This synthesis supports sustainable patient access and long-term strategic leadership for market participants.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. Market Share Analysis, 2025
3.5. FPNV Positioning Matrix, 2025
3.6. New Revenue Opportunities
3.7. Next-Generation Business Models
3.8. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Porter’s Five Forces Analysis
4.4. PESTLE Analysis
4.5. Market Outlook
4.5.1. Near-Term Market Outlook (0-2 Years)
4.5.2. Medium-Term Market Outlook (3-5 Years)
4.5.3. Long-Term Market Outlook (5-10 Years)
4.6. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of United States Tariffs 2025
7. Cumulative Impact of Artificial Intelligence 2025
8. Viral Vectors Market, by Vector Type
8.1. Adeno Associated Virus
8.1.1. AAV2
8.1.2. AAV8
8.1.3. AAV9
8.2. Adenovirus
8.3. Lentivirus
8.4. Retrovirus
9. Viral Vectors Market, by Therapeutic Area
9.1. Cardiovascular Disorders
9.1.1. Coronary
9.1.2. Peripheral Vascular
9.2. Infectious Disease
9.2.1. Bacterial
9.2.2. Viral
9.3. Neurological Disorders
9.3.1. Neurodegenerative
9.3.2. Neurodevelopmental
9.4. Oncology
9.4.1. Hematological
9.4.2. Solid Tumor
9.5. Rare Diseases
10. Viral Vectors Market, by Production Stage
10.1. Downstream
10.1.1. Filtration
10.1.2. Formulation
10.1.3. Purification
10.1.3.1. Chromatography
10.1.3.2. Ultracentrifugation
10.2. Upstream
10.2.1. Cell Expansion
10.2.2. Harvesting
10.2.3. Transfection
11. Viral Vectors Market, by Application
11.1. Cell Therapy
11.1.1. Car T
11.1.2. Dendritic
11.1.3. TCR T
11.2. Gene Therapy
11.2.1. Ex Vivo
11.2.2. In Vivo
11.3. Research
11.3.1. Basic Research
11.3.2. Preclinical Research
11.4. Vaccine
11.4.1. Prophylactic
11.4.2. Therapeutic
12. Viral Vectors Market, by End User
12.1. Biopharma Companies
12.2. Hospitals And Clinics
12.3. Research Institutes
13. Viral Vectors Market, by Region
13.1. Americas
13.1.1. North America
13.1.2. Latin America
13.2. Europe, Middle East & Africa
13.2.1. Europe
13.2.2. Middle East
13.2.3. Africa
13.3. Asia-Pacific
14. Viral Vectors Market, by Group
14.1. ASEAN
14.2. GCC
14.3. European Union
14.4. BRICS
14.5. G7
14.6. NATO
15. Viral Vectors Market, by Country
15.1. United States
15.2. Canada
15.3. Mexico
15.4. Brazil
15.5. United Kingdom
15.6. Germany
15.7. France
15.8. Russia
15.9. Italy
15.10. Spain
15.11. China
15.12. India
15.13. Japan
15.14. Australia
15.15. South Korea
16. United States Viral Vectors Market
17. China Viral Vectors Market
18. Competitive Landscape
18.1. Market Concentration Analysis, 2025
18.1.1. Concentration Ratio (CR)
18.1.2. Herfindahl Hirschman Index (HHI)
18.2. Recent Developments & Impact Analysis, 2025
18.3. Product Portfolio Analysis, 2025
18.4. Benchmarking Analysis, 2025
18.5. ABL Inc.
18.6. Batavia Biosciences B.V. by CJ Cheiljedang
18.7. Biovian Oy
18.8. Charles River Laboratories International, Inc.
18.9. Creative Biogene
18.10. Danaher Corporation
18.11. FinVector Oy
18.12. FUJIFILM Diosynth Biotechnologies U.S.A., Inc.
18.13. GE HealthCare Technologies, Inc.
18.14. Genezen Laboratories, Inc.
18.15. Kaneka Eurogentec S.A.
18.16. Lonza Group Ltd.
18.17. Merck KGaA
18.18. Miltenyi Biotec GmbH
18.19. Novartis AG
18.20. Oxford Biomedica PLC
18.21. Sanofi SA
18.22. Sirion-Biotech GmbH
18.23. Spark Therapeutics, Inc. by F. Hoffmann-La Roche Ltd.
18.24. Takara Bio Inc.
18.25. Thermo Fisher Scientific Inc.
18.26. uniQure N.V.
18.27. VGXI, Inc. by GeneOne Life Science
18.28. Waisman Biomanufacturing
18.29. Wuxi AppTec Co., Ltd.
List of Figures
FIGURE 1. GLOBAL VIRAL VECTORS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 2. GLOBAL VIRAL VECTORS MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 3. GLOBAL VIRAL VECTORS MARKET, FPNV POSITIONING MATRIX, 2025
FIGURE 4. GLOBAL VIRAL VECTORS MARKET SIZE, BY VECTOR TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 5. GLOBAL VIRAL VECTORS MARKET SIZE, BY THERAPEUTIC AREA, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 6. GLOBAL VIRAL VECTORS MARKET SIZE, BY PRODUCTION STAGE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 7. GLOBAL VIRAL VECTORS MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL VIRAL VECTORS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 9. GLOBAL VIRAL VECTORS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL VIRAL VECTORS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 11. GLOBAL VIRAL VECTORS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 12. UNITED STATES VIRAL VECTORS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 13. CHINA VIRAL VECTORS MARKET SIZE, 2018-2032 (USD MILLION)
List of Tables
TABLE 1. GLOBAL VIRAL VECTORS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 2. GLOBAL VIRAL VECTORS MARKET SIZE, BY VECTOR TYPE, 2018-2032 (USD MILLION)
TABLE 3. GLOBAL VIRAL VECTORS MARKET SIZE, BY ADENO ASSOCIATED VIRUS, BY REGION, 2018-2032 (USD MILLION)
TABLE 4. GLOBAL VIRAL VECTORS MARKET SIZE, BY ADENO ASSOCIATED VIRUS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 5. GLOBAL VIRAL VECTORS MARKET SIZE, BY ADENO ASSOCIATED VIRUS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 6. GLOBAL VIRAL VECTORS MARKET SIZE, BY ADENO ASSOCIATED VIRUS, 2018-2032 (USD MILLION)
TABLE 7. GLOBAL VIRAL VECTORS MARKET SIZE, BY AAV2, BY REGION, 2018-2032 (USD MILLION)
TABLE 8. GLOBAL VIRAL VECTORS MARKET SIZE, BY AAV2, BY GROUP, 2018-2032 (USD MILLION)
TABLE 9. GLOBAL VIRAL VECTORS MARKET SIZE, BY AAV2, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 10. GLOBAL VIRAL VECTORS MARKET SIZE, BY AAV8, BY REGION, 2018-2032 (USD MILLION)
TABLE 11. GLOBAL VIRAL VECTORS MARKET SIZE, BY AAV8, BY GROUP, 2018-2032 (USD MILLION)
TABLE 12. GLOBAL VIRAL VECTORS MARKET SIZE, BY AAV8, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 13. GLOBAL VIRAL VECTORS MARKET SIZE, BY AAV9, BY REGION, 2018-2032 (USD MILLION)
TABLE 14. GLOBAL VIRAL VECTORS MARKET SIZE, BY AAV9, BY GROUP, 2018-2032 (USD MILLION)
TABLE 15. GLOBAL VIRAL VECTORS MARKET SIZE, BY AAV9, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 16. GLOBAL VIRAL VECTORS MARKET SIZE, BY ADENOVIRUS, BY REGION, 2018-2032 (USD MILLION)
TABLE 17. GLOBAL VIRAL VECTORS MARKET SIZE, BY ADENOVIRUS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 18. GLOBAL VIRAL VECTORS MARKET SIZE, BY ADENOVIRUS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 19. GLOBAL VIRAL VECTORS MARKET SIZE, BY LENTIVIRUS, BY REGION, 2018-2032 (USD MILLION)
TABLE 20. GLOBAL VIRAL VECTORS MARKET SIZE, BY LENTIVIRUS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 21. GLOBAL VIRAL VECTORS MARKET SIZE, BY LENTIVIRUS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 22. GLOBAL VIRAL VECTORS MARKET SIZE, BY RETROVIRUS, BY REGION, 2018-2032 (USD MILLION)
TABLE 23. GLOBAL VIRAL VECTORS MARKET SIZE, BY RETROVIRUS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 24. GLOBAL VIRAL VECTORS MARKET SIZE, BY RETROVIRUS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 25. GLOBAL VIRAL VECTORS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
TABLE 26. GLOBAL VIRAL VECTORS MARKET SIZE, BY CARDIOVASCULAR DISORDERS, BY REGION, 2018-2032 (USD MILLION)
TABLE 27. GLOBAL VIRAL VECTORS MARKET SIZE, BY CARDIOVASCULAR DISORDERS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 28. GLOBAL VIRAL VECTORS MARKET SIZE, BY CARDIOVASCULAR DISORDERS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 29. GLOBAL VIRAL VECTORS MARKET SIZE, BY CARDIOVASCULAR DISORDERS, 2018-2032 (USD MILLION)
TABLE 30. GLOBAL VIRAL VECTORS MARKET SIZE, BY CORONARY, BY REGION, 2018-2032 (USD MILLION)
TABLE 31. GLOBAL VIRAL VECTORS MARKET SIZE, BY CORONARY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 32. GLOBAL VIRAL VECTORS MARKET SIZE, BY CORONARY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 33. GLOBAL VIRAL VECTORS MARKET SIZE, BY PERIPHERAL VASCULAR, BY REGION, 2018-2032 (USD MILLION)
TABLE 34. GLOBAL VIRAL VECTORS MARKET SIZE, BY PERIPHERAL VASCULAR, BY GROUP, 2018-2032 (USD MILLION)
TABLE 35. GLOBAL VIRAL VECTORS MARKET SIZE, BY PERIPHERAL VASCULAR, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 36. GLOBAL VIRAL VECTORS MARKET SIZE, BY INFECTIOUS DISEASE, BY REGION, 2018-2032 (USD MILLION)
TABLE 37. GLOBAL VIRAL VECTORS MARKET SIZE, BY INFECTIOUS DISEASE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 38. GLOBAL VIRAL VECTORS MARKET SIZE, BY INFECTIOUS DISEASE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 39. GLOBAL VIRAL VECTORS MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2032 (USD MILLION)
TABLE 40. GLOBAL VIRAL VECTORS MARKET SIZE, BY BACTERIAL, BY REGION, 2018-2032 (USD MILLION)
TABLE 41. GLOBAL VIRAL VECTORS MARKET SIZE, BY BACTERIAL, BY GROUP, 2018-2032 (USD MILLION)
TABLE 42. GLOBAL VIRAL VECTORS MARKET SIZE, BY BACTERIAL, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 43. GLOBAL VIRAL VECTORS MARKET SIZE, BY VIRAL, BY REGION, 2018-2032 (USD MILLION)
TABLE 44. GLOBAL VIRAL VECTORS MARKET SIZE, BY VIRAL, BY GROUP, 2018-2032 (USD MILLION)
TABLE 45. GLOBAL VIRAL VECTORS MARKET SIZE, BY VIRAL, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 46. GLOBAL VIRAL VECTORS MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY REGION, 2018-2032 (USD MILLION)
TABLE 47. GLOBAL VIRAL VECTORS MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 48. GLOBAL VIRAL VECTORS MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 49. GLOBAL VIRAL VECTORS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
TABLE 50. GLOBAL VIRAL VECTORS MARKET SIZE, BY NEURODEGENERATIVE, BY REGION, 2018-2032 (USD MILLION)
TABLE 51. GLOBAL VIRAL VECTORS MARKET SIZE, BY NEURODEGENERATIVE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 52. GLOBAL VIRAL VECTORS MARKET SIZE, BY NEURODEGENERATIVE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 53. GLOBAL VIRAL VECTORS MARKET SIZE, BY NEURODEVELOPMENTAL, BY REGION, 2018-2032 (USD MILLION)
TABLE 54. GLOBAL VIRAL VECTORS MARKET SIZE, BY NEURODEVELOPMENTAL, BY GROUP, 2018-2032 (USD MILLION)
TABLE 55. GLOBAL VIRAL VECTORS MARKET SIZE, BY NEURODEVELOPMENTAL, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 56. GLOBAL VIRAL VECTORS MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2032 (USD MILLION)
TABLE 57. GLOBAL VIRAL VECTORS MARKET SIZE, BY ONCOLOGY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 58. GLOBAL VIRAL VECTORS MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 59. GLOBAL VIRAL VECTORS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
TABLE 60. GLOBAL VIRAL VECTORS MARKET SIZE, BY HEMATOLOGICAL, BY REGION, 2018-2032 (USD MILLION)
TABLE 61. GLOBAL VIRAL VECTORS MARKET SIZE, BY HEMATOLOGICAL, BY GROUP, 2018-2032 (USD MILLION)
TABLE 62. GLOBAL VIRAL VECTORS MARKET SIZE, BY HEMATOLOGICAL, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 63. GLOBAL VIRAL VECTORS MARKET SIZE, BY SOLID TUMOR, BY REGION, 2018-2032 (USD MILLION)
TABLE 64. GLOBAL VIRAL VECTORS MARKET SIZE, BY SOLID TUMOR, BY GROUP, 2018-2032 (USD MILLION)
TABLE 65. GLOBAL VIRAL VECTORS MARKET SIZE, BY SOLID TUMOR, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 66. GLOBAL VIRAL VECTORS MARKET SIZE, BY RARE DISEASES, BY REGION, 2018-2032 (USD MILLION)
TABLE 67. GLOBAL VIRAL VECTORS MARKET SIZE, BY RARE DISEASES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 68. GLOBAL VIRAL VECTORS MARKET SIZE, BY RARE DISEASES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 69. GLOBAL VIRAL VECTORS MARKET SIZE, BY PRODUCTION STAGE, 2018-2032 (USD MILLION)
TABLE 70. GLOBAL VIRAL VECTORS MARKET SIZE, BY DOWNSTREAM, BY REGION, 2018-2032 (USD MILLION)
TABLE 71. GLOBAL VIRAL VECTORS MARKET SIZE, BY DOWNSTREAM, BY GROUP, 2018-2032 (USD MILLION)
TABLE 72. GLOBAL VIRAL VECTORS MARKET SIZE, BY DOWNSTREAM, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 73. GLOBAL VIRAL VECTORS MARKET SIZE, BY DOWNSTREAM, 2018-2032 (USD MILLION)
TABLE 74. GLOBAL VIRAL VECTORS MARKET SIZE, BY FILTRATION, BY REGION, 2018-2032 (USD MILLION)
TABLE 75. GLOBAL VIRAL VECTORS MARKET SIZE, BY FILTRATION, BY GROUP, 2018-2032 (USD MILLION)
TABLE 76. GLOBAL VIRAL VECTORS MARKET SIZE, BY FILTRATION, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 77. GLOBAL VIRAL VECTORS MARKET SIZE, BY FORMULATION, BY REGION, 2018-2032 (USD MILLION)
TABLE 78. GLOBAL VIRAL VECTORS MARKET SIZE, BY FORMULATION, BY GROUP, 2018-2032 (USD MILLION)
TABLE 79. GLOBAL VIRAL VECTORS MARKET SIZE, BY FORMULATION, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 80. GLOBAL VIRAL VECTORS MARKET SIZE, BY PURIFICATION, BY REGION, 2018-2032 (USD MILLION)
TABLE 81. GLOBAL VIRAL VECTORS MARKET SIZE, BY PURIFICATION, BY GROUP, 2018-2032 (USD MILLION)
TABLE 82. GLOBAL VIRAL VECTORS MARKET SIZE, BY PURIFICATION, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 83. GLOBAL VIRAL VECTORS MARKET SIZE, BY PURIFICATION, 2018-2032 (USD MILLION)
TABLE 84. GLOBAL VIRAL VECTORS MARKET SIZE, BY CHROMATOGRAPHY, BY REGION, 2018-2032 (USD MILLION)
TABLE 85. GLOBAL VIRAL VECTORS MARKET SIZE, BY CHROMATOGRAPHY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 86. GLOBAL VIRAL VECTORS MARKET SIZE, BY CHROMATOGRAPHY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 87. GLOBAL VIRAL VECTORS MARKET SIZE, BY ULTRACENTRIFUGATION, BY REGION, 2018-2032 (USD MILLION)
TABLE 88. GLOBAL VIRAL VECTORS MARKET SIZE, BY ULTRACENTRIFUGATION, BY GROUP, 2018-2032 (USD MILLION)
TABLE 89. GLOBAL VIRAL VECTORS MARKET SIZE, BY ULTRACENTRIFUGATION, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 90. GLOBAL VIRAL VECTORS MARKET SIZE, BY UPSTREAM, BY REGION, 2018-2032 (USD MILLION)
TABLE 91. GLOBAL VIRAL VECTORS MARKET SIZE, BY UPSTREAM, BY GROUP, 2018-2032 (USD MILLION)
TABLE 92. GLOBAL VIRAL VECTORS MARKET SIZE, BY UPSTREAM, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 93. GLOBAL VIRAL VECTORS MARKET SIZE, BY UPSTREAM, 2018-2032 (USD MILLION)
TABLE 94. GLOBAL VIRAL VECTORS MARKET SIZE, BY CELL EXPANSION, BY REGION, 2018-2032 (USD MILLION)
TABLE 95. GLOBAL VIRAL VECTORS MARKET SIZE, BY CELL EXPANSION, BY GROUP, 2018-2032 (USD MILLION)
TABLE 96. GLOBAL VIRAL VECTORS MARKET SIZE, BY CELL EXPANSION, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 97. GLOBAL VIRAL VECTORS MARKET SIZE, BY HARVESTING, BY REGION, 2018-2032 (USD MILLION)
TABLE 98. GLOBAL VIRAL VECTORS MARKET SIZE, BY HARVESTING, BY GROUP, 2018-2032 (USD MILLION)
TABLE 99. GLOBAL VIRAL VECTORS MARKET SIZE, BY HARVESTING, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 100. GLOBAL VIRAL VECTORS MARKET SIZE, BY TRANSFECTION, BY REGION, 2018-2032 (USD MILLION)
TABLE 101. GLOBAL VIRAL VECTORS MARKET SIZE, BY TRANSFECTION, BY GROUP, 2018-2032 (USD MILLION)
TABLE 102. GLOBAL VIRAL VECTORS MARKET SIZE, BY TRANSFECTION, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 103. GLOBAL VIRAL VECTORS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 104. GLOBAL VIRAL VECTORS MARKET SIZE, BY CELL THERAPY, BY REGION, 2018-2032 (USD MILLION)
TABLE 105. GLOBAL VIRAL VECTORS MARKET SIZE, BY CELL THERAPY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 106. GLOBAL VIRAL VECTORS MARKET SIZE, BY CELL THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 107. GLOBAL VIRAL VECTORS MARKET SIZE, BY CELL THERAPY, 2018-2032 (USD MILLION)
TABLE 108. GLOBAL VIRAL VECTORS MARKET SIZE, BY CAR T, BY REGION, 2018-2032 (USD MILLION)
TABLE 109. GLOBAL VIRAL VECTORS MARKET SIZE, BY CAR T, BY GROUP, 2018-2032 (USD MILLION)
TABLE 110. GLOBAL VIRAL VECTORS MARKET SIZE, BY CAR T, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 111. GLOBAL VIRAL VECTORS MARKET SIZE, BY DENDRITIC, BY REGION, 2018-2032 (USD MILLION)
TABLE 112. GLOBAL VIRAL VECTORS MARKET SIZE, BY DENDRITIC, BY GROUP, 2018-2032 (USD MILLION)
TABLE 113. GLOBAL VIRAL VECTORS MARKET SIZE, BY DENDRITIC, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 114. GLOBAL VIRAL VECTORS MARKET SIZE, BY TCR T, BY REGION, 2018-2032 (USD MILLION)
TABLE 115. GLOBAL VIRAL VECTORS MARKET SIZE, BY TCR T, BY GROUP, 2018-2032 (USD MILLION)
TABLE 116. GLOBAL VIRAL VECTORS MARKET SIZE, BY TCR T, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 117. GLOBAL VIRAL VECTORS MARKET SIZE, BY GENE THERAPY, BY REGION, 2018-2032 (USD MILLION)
TABLE 118. GLOBAL VIRAL VECTORS MARKET SIZE, BY GENE THERAPY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 119. GLOBAL VIRAL VECTORS MARKET SIZE, BY GENE THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 120. GLOBAL VIRAL VECTORS MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
TABLE 121. GLOBAL VIRAL VECTORS MARKET SIZE, BY EX VIVO, BY REGION, 2018-2032 (USD MILLION)
TABLE 122. GLOBAL VIRAL VECTORS MARKET SIZE, BY EX VIVO, BY GROUP, 2018-2032 (USD MILLION)
TABLE 123. GLOBAL VIRAL VECTORS MARKET SIZE, BY EX VIVO, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 124. GLOBAL VIRAL VECTORS MARKET SIZE, BY IN VIVO, BY REGION, 2018-2032 (USD MILLION)
TABLE 125. GLOBAL VIRAL VECTORS MARKET SIZE, BY IN VIVO, BY GROUP, 2018-2032 (USD MILLION)
TABLE 126. GLOBAL VIRAL VECTORS MARKET SIZE, BY IN VIVO, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 127. GLOBAL VIRAL VECTORS MARKET SIZE, BY RESEARCH, BY REGION, 2018-2032 (USD MILLION)
TABLE 128. GLOBAL VIRAL VECTORS MARKET SIZE, BY RESEARCH, BY GROUP, 2018-2032 (USD MILLION)
TABLE 129. GLOBAL VIRAL VECTORS MARKET SIZE, BY RESEARCH, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 130. GLOBAL VIRAL VECTORS MARKET SIZE, BY RESEARCH, 2018-2032 (USD MILLION)
TABLE 131. GLOBAL VIRAL VECTORS MARKET SIZE, BY BASIC RESEARCH, BY REGION, 2018-2032 (USD MILLION)
TABLE 132. GLOBAL VIRAL VECTORS MARKET SIZE, BY BASIC RESEARCH, BY GROUP, 2018-2032 (USD MILLION)
TABLE 133. GLOBAL VIRAL VECTORS MARKET SIZE, BY BASIC RESEARCH, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 134. GLOBAL VIRAL VECTORS MARKET SIZE, BY PRECLINICAL RESEARCH, BY REGION, 2018-2032 (USD MILLION)
TABLE 135. GLOBAL VIRAL VECTORS MARKET SIZE, BY PRECLINICAL RESEARCH, BY GROUP, 2018-2032 (USD MILLION)
TABLE 136. GLOBAL VIRAL VECTORS MARKET SIZE, BY PRECLINICAL RESEARCH, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 137. GLOBAL VIRAL VECTORS MARKET SIZE, BY VACCINE, BY REGION, 2018-2032 (USD MILLION)
TABLE 138. GLOBAL VIRAL VECTORS MARKET SIZE, BY VACCINE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 139. GLOBAL VIRAL VECTORS MARKET SIZE, BY VACCINE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 140. GLOBAL VIRAL VECTORS MARKET SIZE, BY VACCINE, 2018-2032 (USD MILLION)
TABLE 141. GLOBAL VIRAL VECTORS MARKET SIZE, BY PROPHYLACTIC, BY REGION, 2018-2032 (USD MILLION)
TABLE 142. GLOBAL VIRAL VECTORS MARKET SIZE, BY PROPHYLACTIC, BY GROUP, 2018-2032 (USD MILLION)
TABLE 143. GLOBAL VIRAL VECTORS MARKET SIZE, BY PROPHYLACTIC, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 144. GLOBAL VIRAL VECTORS MARKET SIZE, BY THERAPEUTIC, BY REGION, 2018-2032 (USD MILLION)
TABLE 145. GLOBAL VIRAL VECTORS MARKET SIZE, BY THERAPEUTIC, BY GROUP, 2018-2032 (USD MILLION)
TABLE 146. GLOBAL VIRAL VECTORS MARKET SIZE, BY THERAPEUTIC, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 147. GLOBAL VIRAL VECTORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 148. GLOBAL VIRAL VECTORS MARKET SIZE, BY BIOPHARMA COMPANIES, BY REGION, 2018-2032 (USD MILLION)
TABLE 149. GLOBAL VIRAL VECTORS MARKET SIZE, BY BIOPHARMA COMPANIES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 150. GLOBAL VIRAL VECTORS MARKET SIZE, BY BIOPHARMA COMPANIES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 151. GLOBAL VIRAL VECTORS MARKET SIZE, BY HOSPITALS AND CLINICS, BY REGION, 2018-2032 (USD MILLION)
TABLE 152. GLOBAL VIRAL VECTORS MARKET SIZE, BY HOSPITALS AND CLINICS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 153. GLOBAL VIRAL VECTORS MARKET SIZE, BY HOSPITALS AND CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 154. GLOBAL VIRAL VECTORS MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
TABLE 155. GLOBAL VIRAL VECTORS MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 156. GLOBAL VIRAL VECTORS MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 157. GLOBAL VIRAL VECTORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 158. AMERICAS VIRAL VECTORS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
TABLE 159. AMERICAS VIRAL VECTORS MARKET SIZE, BY VECTOR TYPE, 2018-2032 (USD MILLION)
TABLE 160. AMERICAS VIRAL VECTORS MARKET SIZE, BY ADENO ASSOCIATED VIRUS, 2018-2032 (USD MILLION)
TABLE 161. AMERICAS VIRAL VECTORS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
TABLE 162. AMERICAS VIRAL VECTORS MARKET SIZE, BY CARDIOVASCULAR DISORDERS, 2018-2032 (USD MILLION)
TABLE 163. AMERICAS VIRAL VECTORS MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2032 (USD MILLION)
TABLE 164. AMERICAS VIRAL VECTORS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
TABLE 165. AMERICAS VIRAL VECTORS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
TABLE 166. AMERICAS VIRAL VECTORS MARKET SIZE, BY PRODUCTION STAGE, 2018-2032 (USD MILLION)
TABLE 167. AMERICAS VIRAL VECTORS MARKET SIZE, BY DOWNSTREAM, 2018-2032 (USD MILLION)
TABLE 168. AMERICAS VIRAL VECTORS MARKET SIZE, BY PURIFICATION, 2018-2032 (USD MILLION)
TABLE 169. AMERICAS VIRAL VECTORS MARKET SIZE, BY UPSTREAM, 2018-2032 (USD MILLION)
TABLE 170. AMERICAS VIRAL VECTORS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 171. AMERICAS VIRAL VECTORS MARKET SIZE, BY CELL THERAPY, 2018-2032 (USD MILLION)
TABLE 172. AMERICAS VIRAL VECTORS MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
TABLE 173. AMERICAS VIRAL VECTORS MARKET SIZE, BY RESEARCH, 2018-2032 (USD MILLION)
TABLE 174. AMERICAS VIRAL VECTORS MARKET SIZE, BY VACCINE, 2018-2032 (USD MILLION)
TABLE 175. AMERICAS VIRAL VECTORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 176. NORTH AMERICA VIRAL VECTORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 177. NORTH AMERICA VIRAL VECTORS MARKET SIZE, BY VECTOR TYPE, 2018-2032 (USD MILLION)
TABLE 178. NORTH AMERICA VIRAL VECTORS MARKET SIZE, BY ADENO ASSOCIATED VIRUS, 2018-2032 (USD MILLION)
TABLE 179. NORTH AMERICA VIRAL VECTORS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
TABLE 180. NORTH AMERICA VIRAL VECTORS MARKET SIZE, BY CARDIOVASCULAR DISORDERS, 2018-2032 (USD MILLION)
TABLE 181. NORTH AMERICA VIRAL VECTORS MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2032 (USD MILLION)
TABLE 182. NORTH AMERICA VIRAL VECTORS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
TABLE 183. NORTH AMERICA VIRAL VECTORS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
TABLE 184. NORTH AMERICA VIRAL VECTORS MARKET SIZE, BY PRODUCTION STAGE, 2018-2032 (USD MILLION)
TABLE 185. NORTH AMERICA VIRAL VECTORS MARKET SIZE, BY DOWNSTREAM, 2018-2032 (USD MILLION)
TABLE 186. NORTH AMERICA VIRAL VECTORS MARKET SIZE, BY PURIFICATION, 2018-2032 (USD MILLION)
TABLE 187. NORTH AMERICA VIRAL VECTORS MARKET SIZE, BY UPSTREAM, 2018-2032 (USD MILLION)
TABLE 188. NORTH AMERICA VIRAL VECTORS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 189. NORTH AMERICA VIRAL VECTORS MARKET SIZE, BY CELL THERAPY, 2018-2032 (USD MILLION)
TABLE 190. NORTH AMERICA VIRAL VECTORS MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
TABLE 191. NORTH AMERICA VIRAL VECTORS MARKET SIZE, BY RESEARCH, 2018-2032 (USD MILLION)
TABLE 192. NORTH AMERICA VIRAL VECTORS MARKET SIZE, BY VACCINE, 2018-2032 (USD MILLION)
TABLE 193. NORTH AMERICA VIRAL VECTORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 194. LATIN AMERICA VIRAL VECTORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 195. LATIN AMERICA VIRAL VECTORS MARKET SIZE, BY VECTOR TYPE, 2018-2032 (USD MILLION)
TABLE 196. LATIN AMERICA VIRAL VECTORS MARKET SIZE, BY ADENO ASSOCIATED VIRUS, 2018-2032 (USD MILLION)
TABLE 197. LATIN AMERICA VIRAL VECTORS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
TABLE 198. LATIN AMERICA VIRAL VECTORS MARKET SIZE, BY CARDIOVASCULAR DISORDERS, 2018-2032 (USD MILLION)
TABLE 199. LATIN AMERICA VIRAL VECTORS MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2032 (USD MILLION)
TABLE 200. LATIN AMERICA VIRAL VECTORS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
TABLE 201. LATIN AMERICA VIRAL VECTORS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
TABLE 202. LATIN AMERICA VIRAL VECTORS MARKET SIZE, BY PRODUCTION STAGE, 2018-2032 (USD MILLION)
TABLE 203. LATIN AMERICA VIRAL VECTORS MARKET SIZE, BY DOWNSTREAM, 2018-2032 (USD MILLION)
TABLE 204. LATIN AMERICA VIRAL VECTORS MARKET SIZE, BY PURIFICATION, 2018-2032 (USD MILLION)
TABLE 205. LATIN AMERICA VIRAL VECTORS MARKET SIZE, BY UPSTREAM, 2018-2032 (USD MILLION)
TABLE 206. LATIN AMERICA VIRAL VECTORS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 207. LATIN AMERICA VIRAL VECTORS MARKET SIZE, BY CELL THERAPY, 2018-2032 (USD MILLION)
TABLE 208. LATIN AMERICA VIRAL VECTORS MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
TABLE 209. LATIN AMERICA VIRAL VECTORS MARKET SIZE, BY RESEARCH, 2018-2032 (USD MILLION)
TABLE 210. LATIN AMERICA VIRAL VECTORS MARKET SIZE, BY VACCINE, 2018-2032 (USD MILLION)
TABLE 211. LATIN AMERICA VIRAL VECTORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 212. EUROPE, MIDDLE EAST & AFRICA VIRAL VECTORS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
TABLE 213. EUROPE, MIDDLE EAST & AFRICA VIRAL VECTORS MARKET SIZE, BY VECTOR TYPE, 2018-2032 (USD MILLION)
TABLE 214. EUROPE, MIDDLE EAST & AFRICA VIRAL VECTORS MARKET SIZE, BY ADENO ASSOCIATED VIRUS, 2018-2032 (USD MILLION)
TABLE 215. EUROPE, MIDDLE EAST & AFRICA VIRAL VECTORS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
TABLE 216. EUROPE, MIDDLE EAST & AFRICA VIRAL VECTORS MARKET SIZE, BY CARDIOVASCULAR DISORDERS, 2018-2032 (USD MILLION)
TABLE 217. EUROPE, MIDDLE EAST & AFRICA VIRAL VECTORS MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2032 (USD MILLION)
TABLE 218. EUROPE, MIDDLE EAST & AFRICA VIRAL VECTORS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
TABLE 219. EUROPE, MIDDLE EAST & AFRICA VIRAL VECTORS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
TABLE 220. EUROPE, MIDDLE EAST & AFRICA VIRAL VECTORS MARKET SIZE, BY PRODUCTION STAGE, 2018-2032 (USD MILLION)
TABLE 221. EUROPE, MIDDLE EAST & AFRICA VIRAL VECTORS MARKET SIZE, BY DOWNSTREAM, 2018-2032 (USD MILLION)
TABLE 222. EUROPE, MIDDLE EAST & AFRICA VIRAL VECTORS MARKET SIZE, BY PURIFICATION, 2018-2032 (USD MILLION)
TABLE 223. EUROPE, MIDDLE EAST & AFRICA VIRAL VECTORS MARKET SIZE, BY UPSTREAM, 2018-2032 (USD MILLION)
TABLE 224. EUROPE, MIDDLE EAST & AFRICA VIRAL VECTORS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 225. EUROPE, MIDDLE EAST & AFRICA VIRAL VECTORS MARKET SIZE, BY CELL THERAPY, 2018-2032 (USD MILLION)
TABLE 226. EUROPE, MIDDLE EAST & AFRICA VIRAL VECTORS MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
TABLE 227. EUROPE, MIDDLE EAST & AFRICA VIRAL VECTORS MARKET SIZE, BY RESEARCH, 2018-2032 (USD MILLION)
TABLE 228. EUROPE, MIDDLE EAST & AFRICA VIRAL VECTORS MARKET SIZE, BY VACCINE, 2018-2032 (USD MILLION)
TABLE 229. EUROPE, MIDDLE EAST & AFRICA VIRAL VECTORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 230. EUROPE VIRAL VECTORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 231. EUROPE VIRAL VECTORS MARKET SIZE, BY VECTOR TYPE, 2018-2032 (USD MILLION)
TABLE 232. EUROPE VIRAL VECTORS MARKET SIZE, BY ADENO ASSOCIATED VIRUS, 2018-2032 (USD MILLION)
TABLE 233. EUROPE VIRAL VECTORS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
TABLE 234. EUROPE VIRAL VECTORS MARKET SIZE, BY CARDIOVASCULAR DISORDERS, 2018-2032 (USD MILLION)
TABLE 235. EUROPE VIRAL VECTORS MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2032 (USD MILLION)
TABLE 236. EUROPE VIRAL VECTORS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
TABLE 237. EUROPE VIRAL VECTORS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
TABLE 238. EUROPE VIRAL VECTORS MARKET SIZE, BY PRODUCTION STAGE, 2018-2032 (USD MILLION)
TABLE 239. EUROPE VIRAL VECTORS MARKET SIZE, BY DOWNSTREAM, 2018-2032 (USD MILLION)
TABLE 240. EUROPE VIRAL VECTORS MARKET SIZE, BY PURIFICATION, 2018-2032 (USD MILLION)
TABLE 241. EUROPE VIRAL VECTORS MARKET SIZE, BY UPSTREAM, 2018-2032 (USD MILLION)
TABLE 242. EUROPE VIRAL VECTORS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 243. EUROPE VIRAL VECTORS MARKET SIZE, BY CELL THERAPY, 2018-2032 (USD MILLION)
TABLE 244. EUROPE VIRAL VECTORS MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
TABLE 245. EUROPE VIRAL VECTORS MARKET SIZE, BY RESEARCH, 2018-2032 (USD MILLION)
TABLE 246. EUROPE VIRAL VECTORS MARKET SIZE, BY VACCINE, 2018-2032 (USD MILLION)
TABLE 247. EUROPE VIRAL VECTORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 248. MIDDLE EAST VIRAL VECTORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 249. MIDDLE EAST VIRAL VECTORS MARKET SIZE, BY VECTOR TYPE, 2018-2032 (USD MILLION)
TABLE 250. MIDDLE EAST VIRAL VECTORS MARKET SIZE, BY ADENO ASSOCIATED VIRUS, 2018-2032 (USD MILLION)
TABLE 251. MIDDLE EAST VIRAL VECTORS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
TABLE 252. MIDDLE EAST VIRAL VECTORS MARKET SIZE, BY CARDIOVASCULAR DISORDERS, 2018-2032 (USD MILLION)
TABLE 253. MIDDLE EAST VIRAL VECTORS MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2032 (USD MILLION)
TABLE 254. MIDDLE EAST VIRAL VECTORS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
TABLE 255. MIDDLE EAST VIRAL VECTORS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
TABLE 256. MIDDLE EAST VIRAL VECTORS MARKET SIZE, BY PRODUCTION STAGE, 2018-2032 (USD MILLION)
TABLE 257. MIDDLE EAST VIRAL VECTORS MARKET SIZE, BY DOWNSTREAM, 2018-2032 (USD MILLION)
TABLE 258. MIDDLE EAST VIRAL VECTORS MARKET SIZE, BY PURIFICATION, 2018-2032 (USD MILLION)
TABLE 259. MIDDLE EAST VIRAL VECTORS MARKET SIZE, BY UPSTREAM, 2018-2032 (USD MILLION)
TABLE 260. MIDDLE EAST VIRAL VECTORS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 261. MIDDLE EAST VIRAL VECTORS MARKET SIZE, BY CELL THERAPY, 2018-2032 (USD MILLION)
TABLE 262. MIDDLE EAST VIRAL VECTORS MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
TABLE 263. MIDDLE EAST VIRAL VECTORS MARKET SIZE, BY RESEARCH, 2018-2032 (USD MILLION)
TABLE 264. MIDDLE EAST VIRAL VECTORS MARKET SIZE, BY VACCINE, 2018-2032 (USD MILLION)
TABLE 265. MIDDLE EAST VIRAL VECTORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 266. AFRICA VIRAL VECTORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 267. AFRICA VIRAL VECTORS MARKET SIZE, BY VECTOR TYPE, 2018-2032 (USD MILLION)
TABLE 268. AFRICA VIRAL VECTORS MARKET SIZE, BY ADENO ASSOCIATED VIRUS, 2018-2032 (USD MILLION)
TABLE 269. AFRICA VIRAL VECTORS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
TABLE 270. AFRICA VIRAL VECTORS MARKET SIZE, BY CARDIOVASCULAR DISORDERS, 2018-2032 (USD MILLION)
TABLE 271. AFRICA VIRAL VECTORS MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2032 (USD MILLION)
TABLE 272. AFRICA VIRAL VECTORS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
TABLE 273. AFRICA VIRAL VECTORS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
TABLE 274. AFRICA VIRAL VECTORS MARKET SIZE, BY PRODUCTION STAGE, 2018-2032 (USD MILLION)
TABLE 275. AFRICA VIRAL VECTORS MARKET SIZE, BY DOWNSTREAM, 2018-2032 (USD MILLION)
TABLE 276. AFRICA VIRAL VECTORS MARKET SIZE, BY PURIFICATION, 2018-2032 (USD MILLION)
TABLE 277. AFRICA VIRAL VECTORS MARKET SIZE, BY UPSTREAM, 2018-2032 (USD MILLION)
TABLE 278. AFRICA VIRAL VECTORS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 279. AFRICA VIRAL VECTORS MARKET SIZE, BY CELL THERAPY, 2018-2032 (USD MILLION)
TABLE 280. AFRICA VIRAL VECTORS MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
TABLE 281. AFRICA VIRAL VECTORS MARKET SIZE, BY RESEARCH, 2018-2032 (USD MILLION)
TABLE 282. AFRICA VIRAL VECTORS MARKET SIZE, BY VACCINE, 2018-2032 (USD MILLION)
TABLE 283. AFRICA VIRAL VECTORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 284. ASIA-PACIFIC VIRAL VECTORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 285. ASIA-PACIFIC VIRAL VECTORS MARKET SIZE, BY VECTOR TYPE, 2018-2032 (USD MILLION)
TABLE 286. ASIA-PACIFIC VIRAL VECTORS MARKET SIZE, BY ADENO ASSOCIATED VIRUS, 2018-2032 (USD MILLION)
TABLE 287. ASIA-PACIFIC VIRAL VECTORS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
TABLE 288. ASIA-PACIFIC VIRAL VECTORS MARKET SIZE, BY CARDIOVASCULAR DISORDERS, 2018-2032 (USD MILLION)
TABLE 289. ASIA-PACIFIC VIRAL VECTORS MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2032 (USD MILLION)
TABLE 290. ASIA-PACIFIC VIRAL VECTORS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
TABLE 291. ASIA-PACIFIC VIRAL VECTORS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
TABLE 292. ASIA-PACIFIC VIRAL VECTORS MARKET SIZE, BY PRODUCTION STAGE, 2018-2032 (USD MILLION)
TABLE 293. ASIA-PACIFIC VIRAL VECTORS MARKET SIZE, BY DOWNSTREAM, 2018-2032 (USD MILLION)
TABLE 294. ASIA-PACIFIC VIRAL VECTORS MARKET SIZE, BY PURIFICATION, 2018-2032 (USD MILLION)
TABLE 295. ASIA-PACIFIC VIRAL VECTORS MARKET SIZE, BY UPSTREAM, 2018-2032 (USD MILLION)
TABLE 296. ASIA-PACIFIC VIRAL VECTORS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 297. ASIA-PACIFIC VIRAL VECTORS MARKET SIZE, BY CELL THERAPY, 2018-2032 (USD MILLION)
TABLE 298. ASIA-PACIFIC VIRAL VECTORS MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
TABLE 299. ASIA-PACIFIC VIRAL VECTORS MARKET SIZE, BY RESEARCH, 2018-2032 (USD MILLION)
TABLE 300. ASIA-PACIFIC VIRAL VECTORS MARKET SIZE, BY VACCINE, 2018-2032 (USD MILLION)
TABLE 301. ASIA-PACIFIC VIRAL VECTORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 302. GLOBAL VIRAL VECTORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 303. ASEAN VIRAL VECTORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 304. ASEAN VIRAL VECTORS MARKET SIZE, BY VECTOR TYPE, 2018-2032 (USD MILLION)
TABLE 305. ASEAN VIRAL VECTORS MARKET SIZE, BY ADENO ASSOCIATED VIRUS, 2018-2032 (USD MILLION)
TABLE 306. ASEAN VIRAL VECTORS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
TABLE 307. ASEAN VIRAL VECTORS MARKET SIZE, BY CARDIOVASCULAR DISORDERS, 2018-2032 (USD MILLION)
TABLE 308. ASEAN VIRAL VECTORS MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2032 (USD MILLION)
TABLE 309. ASEAN VIRAL VECTORS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
TABLE 310. ASEAN VIRAL VECTORS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
TABLE 311. ASEAN VIRAL VECTORS MARKET SIZE, BY PRODUCTION STAGE, 2018-2032 (USD MILLION)
TABLE 312. ASEAN VIRAL VECTORS MARKET SIZE, BY DOWNSTREAM, 2018-2032 (USD MILLION)
TABLE 313. ASEAN VIRAL VECTORS MARKET SIZE, BY PURIFICATION, 2018-2032 (USD MILLION)
TABLE 314. ASEAN VIRAL VECTORS MARKET SIZE, BY UPSTREAM, 2018-2032 (USD MILLION)
TABLE 315. ASEAN VIRAL VECTORS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 316. ASEAN VIRAL VECTORS MARKET SIZE, BY CELL THERAPY, 2018-2032 (USD MILLION)
TABLE 317. ASEAN VIRAL VECTORS MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
TABLE 318. ASEAN VIRAL VECTORS MARKET SIZE, BY RESEARCH, 2018-2032 (USD MILLION)
TABLE 319. ASEAN VIRAL VECTORS MARKET SIZE, BY VACCINE, 2018-2032 (USD MILLION)
TABLE 320. ASEAN VIRAL VECTORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 321. GCC VIRAL VECTORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 322. GCC VIRAL VECTORS MARKET SIZE, BY VECTOR TYPE, 2018-2032 (USD MILLION)
TABLE 323. GCC VIRAL VECTORS MARKET SIZE, BY ADENO ASSOCIATED VIRUS, 2018-2032 (USD MILLION)
TABLE 324. GCC VIRAL VECTORS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
TABLE 325. GCC VIRAL VECTORS MARKET SIZE, BY CARDIOVASCULAR DISORDERS, 2018-2032 (USD MILLION)
TABLE 326. GCC VIRAL VECTORS MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2032 (USD MILLION)
TABLE 327. GCC VIRAL VECTORS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
TABLE 328. GCC VIRAL VECTORS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
TABLE 329. GCC VIRAL VECTORS MARKET SIZE, BY PRODUCTION STAGE, 2018-2032 (USD MILLION)
TABLE 330. GCC VIRAL VECTORS MARKET SIZE, BY DOWNSTREAM, 2018-2032 (USD MILLION)
TABLE 331. GCC VIRAL VECTORS MARKET SIZE, BY PURIFICATION, 2018-2032 (USD MILLION)
TABLE 332. GCC VIRAL VECTORS MARKET SIZE, BY UPSTREAM, 2018-2032 (USD MILLION)
TABLE 333. GCC VIRAL VECTORS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 334. GCC VIRAL VECTORS MARKET SIZE, BY CELL THERAPY, 2018-2032 (USD MILLION)
TABLE 335. GCC VIRAL VECTORS MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
TABLE 336. GCC VIRAL VECTORS MARKET SIZE, BY RESEARCH, 2018-2032 (USD MILLION)
TABLE 337. GCC VIRAL VECTORS MARKET SIZE, BY VACCINE, 2018-2032 (USD MILLION)
TABLE 338. GCC VIRAL VECTORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 339. EUROPEAN UNION VIRAL VECTORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 340. EUROPEAN UNION VIRAL VECTORS MARKET SIZE, BY VECTOR TYPE, 2018-2032 (USD MILLION)
TABLE 341. EUROPEAN UNION VIRAL VECTORS MARKET SIZE, BY ADENO ASSOCIATED VIRUS, 2018-2032 (USD MILLION)
TABLE 342. EUROPEAN UNION VIRAL VECTORS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
TABLE 343. EUROPEAN UNION VIRAL VECTORS MARKET SIZE, BY CARDIOVASCULAR DISORDERS, 2018-2032 (USD MILLION)
TABLE 344. EUROPEAN UNION VIRAL VECTORS MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2032 (USD MILLION)
TABLE 345. EUROPEAN UNION VIRAL VECTORS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
TABLE 346. EUROPEAN UNION VIRAL VECTORS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
TABLE 347. EUROPEAN UNION VIRAL VECTORS MARKET SIZE, BY PRODUCTION STAGE, 2018-2032 (USD MILLION)
TABLE 348. EUROPEAN UNION VIRAL VECTORS MARKET SIZE, BY DOWNSTREAM, 2018-2032 (USD MILLION)
TABLE 349. EUROPEAN UNION VIRAL VECTORS MARKET SIZE, BY PURIFICATION, 2018-2032 (USD MILLION)
TABLE 350. EUROPEAN UNION VIRAL VECTORS MARKET SIZE, BY UPSTREAM, 2018-2032 (USD MILLION)
TABLE 351. EUROPEAN UNION VIRAL VECTORS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 352. EUROPEAN UNION VIRAL VECTORS MARKET SIZE, BY

Companies Mentioned

The key companies profiled in this Viral Vectors market report include:
  • ABL Inc.
  • Batavia Biosciences B.V. by CJ Cheiljedang
  • Biovian Oy
  • Charles River Laboratories International, Inc.
  • Creative Biogene
  • Danaher Corporation
  • FinVector Oy
  • FUJIFILM Diosynth Biotechnologies U.S.A., Inc.
  • GE HealthCare Technologies, Inc.
  • Genezen Laboratories, Inc.
  • Kaneka Eurogentec S.A.
  • Lonza Group Ltd.
  • Merck KGaA
  • Miltenyi Biotec GmbH
  • Novartis AG
  • Oxford Biomedica PLC
  • Sanofi SA
  • Sirion-Biotech GmbH
  • Spark Therapeutics, Inc. by F. Hoffmann-La Roche Ltd.
  • Takara Bio Inc.
  • Thermo Fisher Scientific Inc.
  • uniQure N.V.
  • VGXI, Inc. by GeneOne Life Science
  • Waisman Biomanufacturing
  • Wuxi AppTec Co., Ltd.

Table Information

Report AttributeDetails
No. of Pages185
PublishedJanuary 2026
Forecast Period2026 - 2032
Estimated Market Value ( USD ) in 2026 $ 2.46 Billion
Forecasted Market Value ( USD ) by 2032 $ 5.6 Billion
Compound Annual Growth Rate14.6%
Regions CoveredGlobal
No. of Companies Mentioned26

Related Topics

Related Reports

Viral Vector Manufacturing Market Report 2025 - Product Image

Viral Vector Manufacturing Market Report 2025

  • Report
  • 250 Pages
  • Global
From
Adeno-Associated Viral Vectors Market Report 2025 - Product Image

Adeno-Associated Viral Vectors Market Report 2025

  • Report
  • 200 Pages
  • Global
From
Adeno-Associated Viral Vectors Market Outlook 2025-2034: Market Share, and Growth Analysis - Product Image

Adeno-Associated Viral Vectors Market Outlook 2025-2034: Market Share, and Growth Analysis

  • Report
  • 160 Pages
  • Global
From
Viral Vectors for Non-Human Primates Market - Global Strategic Business Report - Product Image

Viral Vectors for Non-Human Primates Market - Global Strategic Business Report

  • Report
  • 473 Pages
  • Global
From
Viral Vector Production (Research-Use) Market - Global Strategic Business Report - Product Image

Viral Vector Production (Research-Use) Market - Global Strategic Business Report

  • Report
  • 383 Pages
  • Global
From

About the Viral Vector Market

The Viral Vector market is a subset of the biotechnology industry that focuses on the development and production of viral vectors for gene therapy. Viral vectors are modified viruses that are used to deliver genetic material into cells, allowing for the expression of a desired gene. This technology has been used to treat a variety of diseases, including cancer, genetic disorders, and infectious diseases. Viral vectors are produced through a variety of methods, including recombinant DNA technology, synthetic biology, and cell-based systems. The production of viral vectors requires specialized equipment and expertise, making it a highly specialized field. The Viral Vector market is highly competitive, with a number of companies offering products and services. Some of the major players in the market include Novartis, Merck, Pfizer, AstraZeneca, and Sanofi. Additionally, there are a number of smaller companies that specialize in the production of viral vectors, such as Viralgen, Oxford BioMedica, and Vigene Biosciences. Show Less Read more

Copyright © 2002-2026 Research and Markets. All Rights Reserved.